Statins as regulators of redox state in the vascular endothelium: Beyond lipid lowering

Antioxidants and Redox Signaling

Volumn 20, Issue 8, 2014, Pages 1198-1215

  Margaritis, Marios ^a   Channon, Keith M ^a   Antoniades, Charalambos ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSCRIPTOME;

EID: 84894487816     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5430     Document Type: Review

References (128)

1. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336: 153-162, 1997.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357, 1998.
3. Afilalo J, Majdan AA, and Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921, 2007.
4. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A, Goh N, Rockett KA, and Channon KM. Tetrahydrobiopterindependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 112: 725-735, 2003.
5. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, and Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124: 335-345, 2011.
6. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, and Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 122: S66-S73, 2010.
7. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, and Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 59: 60-70, 2012.
8. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, and Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 30: 1142-1150, 2009.
9. Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, Cunnington C, Tousoulis D, Stefanadis C, Casadei B, Taggart D, Channon KM, and Leeson P. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation 120: S170-S176, 2009.
10. Antonopoulos AS, Antoniades C, Tousoulis D, Bakogiannis C, Demosthenous M, Psarros C, and Stefanadis C. Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 4: 76-87, 2009.
11. Antonopoulos AS, Margaritis M, Shirodaria C, and Antoniades C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 108: 840-848, 2012.
12. Aoki C, Nakano A, Tanaka S, Yanagi K, Ohta S, Jojima T, Kasai K, Takekawa H, Hirata K, and Hattori Y. Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells. Int J Cardiol 156: 55-61, 2012.
13. Boger GI, Rudolph TK, Maas R, Schwedhelm E, Dumbadze E, Bierend A, Benndorf RA, and Boger RH. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral L-arginine. J Am Coll Cardiol 49: 2274-2282, 2007.
14. Boger RH, Maas R, Schulze F, and Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60: 481-487, 2009.
15. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, and Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethioninedependent methyltransferases. Circ Res 87: 99-105, 2000.
16. Brandes RP, Beer S, Ha T, and Busse R. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 1794-1800, 2003.
17. Braunwald E. Biomarkers in heart failure. N Engl J Med 358: 2148-2159, 2008.
18. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, and Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89: 866-873, 2001.
19. Cannon CP, Steinberg BA, Murphy SA, Mega JL, and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48: 438-445, 2006.
20. Cardounel AJ, Xia Y, and Zweier JL. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl-and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 280: 7540-7549, 2005.
21. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, and Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB-and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281: 15099-15109, 2006.
22. Channon KM and Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 53: 515-524, 2002.
23. Chartoumpekis D, Ziros PG, Psyrogiannis A, Kyriazopoulou V, Papavassiliou AG, and Habeos IG. Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Biochem Biophys Res Commun 396: 463-466, 2010.
24. Chen CA, Druhan LJ, Varadharaj S, Chen YR, and Zweier JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol Chem 283: 27038-27047, 2008.
25. Christ M, Bauersachs J, Liebetrau C, Heck M, Gunther A, and Wehling M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51: 2648-2652, 2002.
26. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926-933, 2001.
27. de Sotomayor MA, Perez-Guerrero C, Herrrera MD, Jimenez L, Marin R, Marhuenda E, and Andriantsitohaina R. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. Br J Pharmacol 146: 1130-1138, 2005.
28. Deanfield JE, Halcox JP, and Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285-1295, 2007.
29. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, and Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104: 576-581, 2001.
30. Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, and Maass M. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 108: 261-265, 2003.
31. Di Francesco L, Totani L, Dovizio M, Piccoli A, Di Francesco A, Salvatore T, Pandolfi A, Evangelista V, Dercho RA, Seta F, and Patrignani P. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res 104: 506-513, 2009.
32. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, and Weidinger F. HMGCoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 58-63, 2003.
33. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, and Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45: 1340-1351, 2008.
34. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, and Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107: 106-116, 2010.
35. Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, Sachdev V, Knatterud G, and Braunwald E. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. Am J Cardiol 102: 1023-1027, 2008.
36. Eid HM, Eritsland J, Larsen J, Arnesen H, and Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166: 279-284, 2003.
37. Frei B, Stocker R, and Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85: 9748-9752, 1988.
38. Gokce N, Keaney JF Jr., Hunter LM, Watkins MT, Menzoian JO, and Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 105: 1567-1572, 2002.
39. Golomb BA and Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373-418, 2008.
40. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, and Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 52: 1803-1809, 2008.
41. Hattori Y, Matsumura M, and Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 58: 186-195, 2003.
42. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, and Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 23: 176-182, 2003.
43. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, and Egido J. Simvastatin reduces NFkappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57: 168-177, 2003.
44. Holschermann H, Schuster D, Parviz B, Haberbosch W, Tillmanns H, and Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 185: 240-245, 2006.
45. Hong H, Zeng JS, Kreulen DL, Kaufman DI, and Chen AF. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol 291: H2210-H2215, 2006.
46. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, and Katayama S. Lipophilic HMG-CoA reductase inhibitor has an antiinflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863-876, 2000.
47. Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164, 2001.
48. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, Girgis RE, and Garcia JG. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30: 662-670, 2004.
49. Jiang JL, Wang S, Li NS, Zhang XH, Deng HW, and Li YJ. The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochem Cell Biol 85: 66-77, 2007.
50. Koh KK, Sakuma I, and Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 215: 1-8, 2011.
51. Kosmidou I, Moore JP, Weber M, and Searles CD. Statin treatment and 3¢ polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol 27: 2642-2649, 2007.
52. Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, and Katus HA. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101: 1760-1763, 2000.
53. Kurusu A, Shou I, Nakamura S, Fukui M, Shirato I, and Tomino Y. Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 27: 767-770, 2000.
54. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, and Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111: 2356-2363, 2005.
55. Landmesser U, Hornig B, and Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109: II27-II33, 2004.
56. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
57. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, and Mehta JL. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 302: 601-605, 2002.
58. Liu PY, Liu YW, Lin LJ, Chen JH, and Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119: 131-138, 2009.
59. Liu SL, Li YH, Shi GY, Jiang MJ, Chang JH, and Wu HL. The effect of statin on the aortic gene expression profiling. Int J Cardiol 114: 71-77, 2007.
60. Lonn ME, Dennis JM, and Stocker R. Actions of "antioxidants" in the protection against atherosclerosis. Free Radic Biol Med 53: 863-884, 2012.
61. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, and Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 94: 157-161, 2004.
62. Makabe S, Takahashi Y, Watanabe H, Murakami M, Ohba T, and Ito H. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis 213: 377-384, 2010.
63. Margaritis M, Channon KM, and Antoniades C. Statins and vein graft failure in coronary bypass surgery. Curr Opin Pharmacol 12: 172-180, 2012.
64. Maron BA and Michel T. Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase. Circ J 76: 2497-2512, 2012.
65. Martinez-Gonzalez J, Raposo B, Rodriguez C, and Badimon L. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 21: 804-809, 2001.
66. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, and Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-590, 2012.
67. Mills EJ, O'Regan C, Eyawo O, Wu P, Mills F, Berwanger O, and Briel M. Intensive statin therapy compared wi moderate dosing for prevention of cardiovascular events: a meta-analysis of 40,000 patients. Eur Heart J 32: 1409-1415, 2011.
68. Mitani H, Egashira K, Ohashi N, Yoshikawa M, Niwa S, Nonomura K, Nakashima A, and Kimura M. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Pharmacology 68: 121-130, 2003.
69. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, Kuss O, Adams V, Lenk K, Mohr FW, Schuler G, and Hambrecht R. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 114: I296-I301, 2006.
70. Morgan MJ and Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21: 103-115, 2011.
71. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, and Kodama T. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178-183, 2002.
72. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, and Kodama T. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11: 62-72, 2004.
73. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, and Park BJ. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 346: f10, 2013.
74. Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, Stehouwer CD, van Ittersum FJ, Olthof MR, Teerlink T, Twisk JW, van Guldener C, and Smulders YM. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am J Kidney Dis 53: 41-50, 2009.
75. Ni Chroinin D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Diez-Tejedor E, Di Napoli M, Engelter ST, Furie KL, Giannopoulos S, Gotto AM Jr., Hannon N, Jonsson F, Kapral MK, Marti-Fabregas J, Martinez-Sanchez P, Milionis HJ, Montaner J, Muscari A, Pikija S, Probstfield J, Rost NS, Thrift AG, Vemmos K, and Kelly PJ. Statin therapy and outcome after ischemic stroke: systematic review and metaanalysis of observational studies and randomized trials. Stroke 44: 448-456, 2013.
76. Oguz A and Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 49: 303-311, 2008.
77. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, and Egido J. Atorvastatin reduces NFkappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147: 253-261, 1999.
78. Ortego M, Gomez-Hernandez A, Vidal C, Sanchez-Galan E, Blanco-Colio LM, Martin-Ventura JL, Tunon J, Diaz C, Hernandez G, and Egido J. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol 45: 468-475, 2005.
79. Ostad MA, Eggeling S, Tschentscher P, Schwedhelm E, Boger R, Wenzel P, Meinertz T, Munzel T, and Warnholtz A. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 205: 227-232, 2009.
80. Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, Iijima K, Akishita M, and Ouchi Y. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 30: 2205-2211, 2010.
81. Pacher P, Beckman JS, and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
82. Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davi G, Gallina P, Bon GB, and Patrono C. Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102: 539-545, 2000.
83. Pei Y, Ma P, Wang X, Zhang W, Zhang X, Zheng P, Yan L, Xu Q, and Dai G. Rosuvastatin attenuates monocrotalineinduced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 666: 165-172, 2011.
84. Pelat M, Dessy C, Massion P, Desager JP, Feron O, and Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation 107: 2480-2486, 2003.
85. Pereira EC, Bertolami MC, Faludi AA, Salem M, Bersch D, and Abdalla DS. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res 37: 529-536, 2003.
86. Perez-Guerrero C, Alvarez de Sotomayor M, Jimenez L, Herrera MD, and Marhuenda E. Effects of simvastatin on endothelial function after chronic inhibition of nitric oxide synthase by L-NAME. J Cardiovasc Pharmacol 42: 204-210, 2003.
87. Piechota-Polanczyk A, Goraca A, Demyanets S, Mittlboeck M, Domenig C, Neumayer C, Wojta J, Nanobachvili J, Huk I, and Klinger M. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-kappaB. Eur J Vasc Endovasc Surg 44: 133-137, 2012.
88. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, and Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 30: 360-367, 2010.
89. Potena L, Frascaroli G, Grigioni F, Lazzarotto T, Magnani G, Tomasi L, Coccolo F, Gabrielli L, Magelli C, Landini MP, and Branzi A. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 109: 532-536, 2004.
90. Ras RT, Streppel MT, Draijer R, and Zock PL. Flowmediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol, 2012.
91. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, and Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368-1376, 2011.
92. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Mac-Fadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, and Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008.
93. Rossoni LV, Wareing M, Wenceslau CF, Al-Abri M, Cobb C, and Austin C. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci (Lond) 121: 449-458, 2011.
94. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104: 1767-1772, 2001.
95. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009, 1996.
96. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Tager M, and Bode-Boger SM. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 24: 1816-1822, 2004.
97. Sezer ED, Sozmen EY, Nart D, and Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 7: 333-343, 2011.
98. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307, 1995.
99. Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland JC, Duvillard L, Zeller M, Cottin Y, Vergely C, and Rochette L. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 42: 226-236, 2008.
100. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, and Ekstrom L. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26: 628-636, 2011.
101. Smith SC Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, and Taubert KA. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124: 2458-2473, 2011.
102. Sorrentino S and Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med 7: 459-466, 2005.
103. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, Yan GJ, and Zhou JG. Essential role of microRNA-155 in regulating endotheliumdependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 60: 1407-1414, 2012.
104. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., and Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000.
105. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, and Caldwell RW. Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319: 386-395, 2006.
106. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, and Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816, 2013.
107. Toledano MB and Leonard WJ. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 88: 4328-4332, 1991.
108. Tran CT, Leiper JM, and Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4: 33-40, 2003.
109. Valkonen VP, Laakso J, Paiva H, Lehtimaki T, Lakka TA, Isomustajarvi M, Ruokonen I, Salonen JT, and Laaksonen R. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 4: 19-22, 2003.
110. Vecchione C and Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91: 173-179, 2002.
111. Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, Duranti E, Daghini E, Giannarelli C, Blandizzi C, Taddei S, and Del Tacca M. Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 53: 1008-1016, 2009.
112. Vladimirova-Kitova LG and Deneva-Koycheva TI. The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level: a randomized, placebo-controlled study. Vascul Pharmacol 56: 122-130, 2012.
113. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000.
114. Wang HR, Li JJ, Huang CX, and Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 353: 53-60, 2005.
115. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, and Nickenig G. HMGCoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457, 2001.
116. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22: 300-305, 2002.
117. Wei YM, Li X, Xiong J, Abais JM, Xia M, Boini KM, Zhang Y, and Li PL. Attenuation by statins of membrane raftredox signaling in coronary arterial endothelium. J Pharmacol Exp Ther 345: 170-179, 2013.
118. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, Xu J, Thum T, Bauersachs J, Ertl G, Zou MH, Forstermann U, and Munzel T. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin- induced diabetes mellitus. Atherosclerosis 198: 65-76, 2008.
119. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR Jr., and Lerman A. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 21: 122-128, 2001.
120. Winchester DE, Wen X, Xie L, and Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol 56: 1099-1109, 2010.
121. Young JM, Strey CH, George PM, Florkowski CM, Sies CW, Frampton CM, and Scott RS. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with nonischaemic heart failure. Eur J Heart Fail 10: 463-466, 2008.
122. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, Funk CD, and FitzGerald GA. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4: 132ra54, 2012.
123. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, and Naruszewicz M. Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci 75: 1287-1302, 2004.
124. Zelvyte I, Dominaitiene R, Crisby M, and Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147-154, 2002.
125. Zhang L, Gong D, Li S, and Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 223: 78-85, 2012.
126. Zhang LQ, Ma SF, Grigoryev D, Lavoie TL, Xiao HQ, Setterquist R, Li H, Jacobson J, Garcia JG, and Ye SQ. Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin. Gene Expr 14: 229-239, 2008.
127. Zhou G, Ge S, Liu D, Xu G, Zhang R, Yin Q, Zhu W, Chen J, and Liu X. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 115: 221-228, 2010.
128. Zhu B, Shen H, Zhou J, Lin F, and Hu Y. Effects of simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection. Nephron Exp Nephrol 101: e1-e8, 2005.